{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T15:00:45Z","timestamp":1783350045864,"version":"3.54.6"},"reference-count":32,"publisher":"Galenos Yayinevi","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["tjo"],"published-print":{"date-parts":[[2024,2,22]]},"DOI":"10.4274\/tjo.galenos.2023.58485","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T08:32:52Z","timestamp":1708590772000},"page":"23-31","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of Full-Field Stimulus Threshold Test Results in Retinitis Pigmentosa: Relationship with Full-Field Electroretinography, Multifocal Electroretinography, Optical Coherence Tomography, and Visual Field"],"prefix":"10.4274","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8583-1836","authenticated-orcid":false,"given":"Ay\u015fe","family":"\u00d6ner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1409-1404","authenticated-orcid":false,"given":"Neslihan Sinim","family":"Kahraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4274\/tjo.89972","article-title":"Stem Cell Treatment in Retinal Diseases: Recent Developments","volume":"48","author":"\u00d6ner","year":"2018","unstructured":"1. \u00d6ner A. Stem Cell Treatment in Retinal Diseases: Recent Developments. Turk J Ophthalmol. 2018;48:33-38.","journal-title":"Turk J Ophthalmol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/ICU.0000000000000660","article-title":"Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease","volume":"31","author":"Prado","year":"2020","unstructured":"2. Prado DA, Acosta-Acero M, Maldonado RS. Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease. Curr Opin Ophthalmol. 2020;31:147-154.","journal-title":"Curr Opin Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ymthe.2020.11.029","article-title":"Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy","volume":"29","author":"Maguire","year":"2021","unstructured":"3. Maguire AM, Bennett J, Aleman EM, Leroy BP, Aleman TS. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy. Mol Ther. 2021;29:442-463.","journal-title":"Mol Ther"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13287-016-0432-y","article-title":"Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study","volume":"7","author":"Oner","year":"2016","unstructured":"4. Oner A, Gonen ZB, Sinim N, Cetin M, Ozkul Y. Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study. Stem Cell Res Ther. 2016;7:178.","journal-title":"Stem Cell Res Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.18240\/ijo.2020.09.14","article-title":"Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial","volume":"13","author":"NS","year":"2020","unstructured":"5. Kahraman NS, Oner A. Umbilical cord derived mesenchymal stem cell implantation in retinitis pigmentosa: a 6-month follow-up results of a phase 3 trial. Int J Ophthalmol. 2020;13:1423-1429.","journal-title":"Int J Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13287-020-01870-w","article-title":"Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results","volume":"11","author":"\u00d6zmert E","year":"2020","unstructured":"6. \u00d6zmert E, Arslan U. Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results. Stem Cell Res Ther. 2020;11:353.","journal-title":"Stem Cell Res Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1089\/scd.2020.0037","article-title":"Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Maintains and Partially Improves Visual Function in Patients with Advanced Retinitis Pigmentosa","volume":"29","author":"Zhao","year":"2020","unstructured":"7. Zhao T, Liang Q, Meng X, Duan P, Wang F, Li S, Liu Y, Yin ZQ. Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Maintains and Partially Improves Visual Function in Patients with Advanced Retinitis Pigmentosa. Stem Cells Dev. 2020;29:1029-1037.","journal-title":"Stem Cells Dev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1089\/jop.2020.0017","article-title":"Effect of Transcorneal Electrical Stimulation on Patients with Retinitis Pigmentosa","volume":"36","author":"Kahraman N","year":"2020","unstructured":"8. Sinim Kahraman N, Oner A. Effect of Transcorneal Electrical Stimulation on Patients with Retinitis Pigmentosa. J Ocul Pharmacol Ther. 2020;36:609-617.","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1097\/IAE.0000000000003386","article-title":"Transcorneal electrical stimulation therapy may have a stabilization effect on multifocal electroretinography for patients with retinitis pigmentosa","volume":"42","author":"Dizdar Yigit","year":"2022","unstructured":"9. Dizdar Yigit D, Sevik MO, \u015eahin \u00d6. Transcorneal electrical stimulation therapy may have a stabilization effect on multifocal electroretinography for patients with retinitis pigmentosa. Retina. 2022;42:923-933.","journal-title":"Retina"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1167\/iovs.06-0630","article-title":"Assessment of central retinal function in patients with advanced retinitis pigmentosa","volume":"48","author":"Gerth","year":"2007","unstructured":"10. Gerth C, Wright T, H\u00e9on E, Westall CA. Assessment of central retinal function in patients with advanced retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2007;48:1312-1318.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1046\/j.1475-1313.1998.00374.x","article-title":"Investigation of retinitis pigmentosa using the multifocal electroretinogram","volume":"18","author":"HL","year":"1998","unstructured":"11. Chan HL, Brown B. Investigation of retinitis pigmentosa using the multifocal electroretinogram. Ophthalmic Physiol Opt. 1998;18:335-350.","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1600-0420.2004.00362.x","article-title":"Full-field ERG, multifocal ERG and multifocal VEP in patients with retinitis pigmentosa and residual central visual fields","volume":"82","author":"Gr\u00e4nse","year":"2004","unstructured":"12. Gr\u00e4nse L, Ponjavic V, Andr\u00e9asson S. Full-field ERG, multifocal ERG and multifocal VEP in patients with retinitis pigmentosa and residual central visual fields. Acta Ophthalmol Scand. 2004;82:701-706.","journal-title":"Acta Ophthalmol Scand"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1167\/iovs.07-1360","article-title":"Long-term follow-up of retinitis pigmentosa patients with multifocal electroretinography","volume":"49","author":"Nagy","year":"2008","unstructured":"13. Nagy D, Sch\u00f6nfisch B, Zrenner E, J\u00e4gle H. Long-term follow-up of retinitis pigmentosa patients with multifocal electroretinography. Invest Ophthalmol Vis Sci. 2008;49:4664-4671.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1097\/IAE.0000000000000144","article-title":"Psychophysical measurement of rod and cone thresholds in stargardt disease with full-field stimuli","volume":"34","author":"Collison","year":"2014","unstructured":"14. Collison FT, Fishman GA, McAnany JJ, Zernant J, Allikmets R. Psychophysical measurement of rod and cone thresholds in stargardt disease with full-field stimuli. Retina. 2014;34:1888-1895.","journal-title":"Retina"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10633-013-9393-y","article-title":"Psychophysically determined full-field stimulus thresholds (FST) in retinitis pigmentosa: relationships with electroretinography and visual field outcomes","volume":"127","author":"Messias","year":"2013","unstructured":"15. Messias K, J\u00e4gle H, Saran R, Ruppert AD, Siqueira R, Jorge R, Messias A. Psychophysically determined full-field stimulus thresholds (FST) in retinitis pigmentosa: relationships with electroretinography and visual field outcomes. Doc Ophthalmol. 2013;127:123-129.","journal-title":"Doc Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10633-022-09872-0","article-title":"ISCEV Standard for full-field clinical electroretinography (2022 update)","volume":"144","author":"Robson","year":"2022","unstructured":"16. Robson AG, Frishman LJ, Grigg J, Hamilton R, Jeffrey BG, Kondo M, Li S, McCulloch DL. ISCEV Standard for full-field clinical electroretinography (2022 update). Doc Ophthalmol. 2022;144:165-177.","journal-title":"Doc Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10633-020-09812-w","article-title":"ISCEV standard for clinical multifocal electroretinography (mfERG) (2021 update)","volume":"142","author":"Hoffmann","year":"2021","unstructured":"17. Hoffmann MB, Bach M, Kondo M, Li S, Walker S, Holopigian K, Viswanathan S, Robson AG. ISCEV standard for clinical multifocal electroretinography (mfERG) (2021 update). Doc Ophthalmol. 2021;142:5-16.","journal-title":"Doc Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-0716-2651-1_14","article-title":"Measure of Visual Function","volume":"2560","author":"Hirji","year":"2023","unstructured":"18. Hirji SH. Measure of Visual Function. Methods Mol Biol. 2023;2560:145-151.","journal-title":"Methods Mol Biol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.exer.2004.09.008","article-title":"Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures","volume":"80","author":"Roman","year":"2005","unstructured":"19. Roman AJ, Schwartz SB, Aleman TS, Cideciyan AV, Chico JD, Windsor EA, Gardner LM, Ying GS, Smilko EE, Maguire MG, Jacobson SG. Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res. 2005;80:259-272.","journal-title":"Exp Eye Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1088\/0967-3334\/28\/8\/N02","article-title":"Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials","volume":"28","author":"Roman","year":"2007","unstructured":"20. Roman AJ, Cideciyan AV, Aleman TS, Jacobson SG. Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas. 2007;28:51-56.","journal-title":"Physiol Meas"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1167\/iovs.08-2696","article-title":"Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations","volume":"50","author":"Jacobson","year":"2009","unstructured":"21. Jacobson SG, Aleman TS, Cideciyan AV, Roman AJ, Sumaroka A, Windsor EA, Schwartz SB, Heon E, Stone EM. Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci. 2009;50:2368-2375.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10633-013-9393-y","article-title":"Psychophysically determined full-field stimulus thresholds (FST) in retinitis pigmentosa: relationships with electroretinography and visual field outcomes","volume":"127","author":"Messias","year":"2013","unstructured":"22. Messias K, J\u00e4gle H, Saran R, Ruppert AD, Siqueira R, Jorge R, Messias A. Psychophysically determined full-field stimulus thresholds (FST) in retinitis pigmentosa: relationships with electroretinography and visual field outcomes. Doc Ophthalmol. 2013;127:123-129.","journal-title":"Doc Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"101000","DOI":"10.1016\/j.preteyeres.2021.101000","article-title":"Full-field stimulus testing: Role in the clinic and as an outcome measure in clinical trials of severe childhood retinal disease","volume":"87","author":"Roman","year":"2022","unstructured":"23. Roman AJ, Cideciyan AV, Wu V, Garafalo AV, Jacobson SG. Full-field stimulus testing: Role in the clinic and as an outcome measure in clinical trials of severe childhood retinal disease. Prog Retin Eye Res. 2022;87:101000.","journal-title":"Prog Retin Eye Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10633-009-9204-7","article-title":"Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST)","volume":"119","author":"Klein","year":"2009","unstructured":"24. Klein M, Birch DG. Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST). Doc Ophthalmol. 2009;119:217-224.","journal-title":"Doc Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ajo.2022.07.010","article-title":"Correlations of Full-Field Stimulus Threshold With Functional and Anatomical Outcome Measurements in Advanced Retinitis Pigmentosa","volume":"245","author":"Ngo","year":"2023","unstructured":"25. Ngo WK, Jenny LA, Kim AH, Kolesnikova M, Greenstein VC, Tsang SH. Correlations of Full-Field Stimulus Threshold With Functional and Anatomical Outcome Measurements in Advanced Retinitis Pigmentosa. Am J Ophthalmol. 2023;245:155-163.","journal-title":"Am J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1167\/iovs.09-4945","article-title":"A comparison of visual field sensitivity to photoreceptor thickness in retinitis pigmentosa","volume":"51","author":"Rangaswamy","year":"2010","unstructured":"26. Rangaswamy NV, Patel HM, Locke KG, Hood DC, Birch DG. A comparison of visual field sensitivity to photoreceptor thickness in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2010;51:4213-4219.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1167\/iovs.18-24635","article-title":"Significant Relationship of Visual Field Sensitivity in Central 10\u00b0 to Thickness of Retinal Layers in Retinitis Pigmentosa","volume":"59","author":"Sayo","year":"2018","unstructured":"27. Sayo A, Ueno S, Kominami T, Okado S, Inooka D, Komori S, Terasaki H. Significant Relationship of Visual Field Sensitivity in Central 10\u00b0 to Thickness of Retinal Layers in Retinitis Pigmentosa. Invest Ophthalmol Vis Sci. 2018;59:3469-3475.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/tvst.9.11.9","article-title":"The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline","volume":"9","author":"DG","year":"2020","unstructured":"28. Birch DG, Cheng P, Duncan JL, Ayala AR, Maguire MG, Audo I, Cheetham JK, Durham TA, Fahim AT, Ferris FL 3rd, Heon E, Huckfeldt RM, Iannaccone A, Khan NW, Lad EM, Michaelides M, Pennesi ME, Stingl K, Vincent A, Weng CY; Foundation Fighting Blindness Consortium Investigator Group. The RUSH2A Study: Best-Corrected Visual Acuity, Full-Field Electroretinography Amplitudes, and Full-Field Stimulus Thresholds at Baseline. Transl Vis Sci Technol. 2020;9:9.","journal-title":"Transl Vis Sci Technol"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, McCague S, Cross D, Marshall KA, Walshire J, Kehoe TL, Reichert H, Davis M, Raffini L, George LA, Hudson FP, Dingfield L, Zhu X, Haller JA, Sohn EH, Mahajan VB, Pfeifer W, Weckmann M, Johnson C, Gewaily D, Drack A, Stone E, Wachtel K, Simonelli F, Leroy BP, Wright JF, High KA, Maguire AM. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390:849-860. Erratum in: Lancet. 2017;390:848.","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials","volume":"126","author":"Maguire","year":"2019","unstructured":"30. Maguire AM, Russell S, Wellman JA, Chung DC, Yu ZF, Tillman A, Wittes J, Pappas J, Elci O, Marshall KA, McCague S, Reichert H, Davis M, Simonelli F, Leroy BP, Wright JF, High KA, Bennett J. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. Ophthalmology. 2019;126:1273-1285.","journal-title":"Ophthalmology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years","volume":"128","author":"Maguire","year":"2021","unstructured":"31. Maguire AM, Russell S, Chung DC, Yu ZF, Tillman A, Drack AV, Simonelli F, Leroy BP, Reape KZ, High KA, Bennett J. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years. Ophthalmology. 2021;128:1460-1468.","journal-title":"Ophthalmology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/s41591-022-01755-w","article-title":"Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial","volume":"28","author":"Russell","year":"2022","unstructured":"32. Russell SR, Drack AV, Cideciyan AV, Jacobson SG, Leroy BP, Van Cauwenbergh C, Ho AC, Dumitrescu AV, Han IC, Martin M, Pfeifer WL, Sohn EH, Walshire J, Garafalo AV, Krishnan AK, Powers CA, Sumaroka A, Roman AJ, Vanhonsebrouck E, Jones E, Nerinckx F, De Zaeytijd J, Collin RWJ, Hoyng C, Adamson P, Cheetham ME, Schwartz MR, den Hollander W, Asmus F, Platenburg G, Rodman D, Girach A. Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b\/2 trial. Nat Med. 2022;28:1014-1021.","journal-title":"Nat Med"}],"container-title":["Turkish Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T13:02:01Z","timestamp":1721998921000},"score":1,"resource":{"primary":{"URL":"https:\/\/oftalmoloji.org\/articles\/doi\/tjo.galenos.2023.58485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,22]]},"published-print":{"date-parts":[[2024,2,22]]}},"URL":"https:\/\/doi.org\/10.4274\/tjo.galenos.2023.58485","relation":{},"ISSN":["1300-0659","2147-2661"],"issn-type":[{"value":"1300-0659","type":"print"},{"value":"2147-2661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}